» Articles » PMID: 33668070

Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019

Abstract

The differentiation between influenza and coronavirus disease 2019 (COVID-19) could constitute a diagnostic challenge during the ongoing winter owing to their clinical similitude. Thus, novel biomarkers are required to enable making this distinction. Here, we evaluated whether the surfactant protein D (SP-D), a collectin produced at the alveolar epithelium with known immune properties, was useful to differentiate pandemic influenza A(H1N1) from COVID-19 in critically ill patients. Our results revealed high serum SP-D levels in patients with severe pandemic influenza but not those with COVID-19. This finding was validated in a separate cohort of mechanically ventilated patients with COVID-19 who also showed low plasma SP-D levels. However, plasma SP-D levels did not distinguish seasonal influenza from COVID-19 in mild-to-moderate disease. Finally, we found that high serum SP-D levels were associated with death and renal failure among severe pandemic influenza cases. Thus, our studies have identified SP-D as a unique biomarker expressed during severe pandemic influenza but not COVID-19.

Citing Articles

Update prognostic potency of surfactant protein D (SP-D) in the COVID-19 landscape: an In-depth meta-analytical exploration.

Bastani M, Jalilian S, Bahreiny S, Makvandi M, Aghaei M, Mansouri Z Biomark Med. 2024; 18(24):1135-1148.

PMID: 39618167 PMC: 11654819. DOI: 10.1080/17520363.2024.2432325.


Unraveling the enigma: The emerging significance of pulmonary surfactant proteins in predicting, diagnosing, and managing COVID-19.

Bastani M, Jalilian S Immun Inflamm Dis. 2024; 12(6):e1302.

PMID: 38860749 PMC: 11165688. DOI: 10.1002/iid3.1302.


Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.

Bauer R, Teterina A, Shivram H, McBride J, Rosenberger C, Cai F Clin Transl Sci. 2023; 16(6):1049-1062.

PMID: 36929625 PMC: 10264938. DOI: 10.1111/cts.13511.


Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection.

Salvioni L, Testa F, Sulejmani A, Pepe F, Lovaglio P, Berta P Clin Chim Acta. 2022; 537:140-145.

PMID: 36341812 PMC: 9617654. DOI: 10.1016/j.cca.2022.10.013.


The Tip of the Spear: Emergency Medicine and Missouri's Response to the COVID-19 Pandemic.

Sampson C, Liang S Mo Med. 2022; 119(5):432-436.

PMID: 36337989 PMC: 9616458.


References
1.
Mudd P, Crawford J, Turner J, Souquette A, Reynolds D, Bender D . Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv. 2020; 6(50). PMC: 7725462. DOI: 10.1126/sciadv.abe3024. View

2.
Castillejos M, Cabello-Gutierrez C, Choreno-Parra J, Hernandez V, Romo J, Hernandez-Sanchez F . High performance of rapid influenza diagnostic test and variable effectiveness of influenza vaccines in Mexico. Int J Infect Dis. 2019; 89:87-95. DOI: 10.1016/j.ijid.2019.08.029. View

3.
Choreno-Parra J, Jimenez-Alvarez L, Cruz-Lagunas A, Rodriguez-Reyna T, Ramirez-Martinez G, Sandoval-Vega M . Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1). Front Immunol. 2021; 12:593595. PMC: 8115405. DOI: 10.3389/fimmu.2021.593595. View

4.
Polak S, Van Gool I, Cohen D, von der Thusen J, van Paassen J . A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020; 33(11):2128-2138. PMC: 7306927. DOI: 10.1038/s41379-020-0603-3. View

5.
Tang X, Du R, Wang R, Cao T, Guan L, Yang C . Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest. 2020; 158(1):195-205. PMC: 7151343. DOI: 10.1016/j.chest.2020.03.032. View